Gwen Pearlman, DO
Endocrinology, Diabetes & Metabolism · Boca Raton, FLNPI 1871515338
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.9% of the total across 281 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 15.9% — the pattern of someone who eats at a lot of different presentations.
Across 281 payments — averaging $18.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$845
- AstraZeneca$788
- Amgen$602
- Novo Nordisk$491
- Exact Sciences$333
- Amneal Pharmaceuticals LLC$276
- plus $2K from 31 others
What the payments were for
- Food & beverage$5,27099%
- Gifts$591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 53 | $845 |
| AstraZeneca | 47 | $788 |
| Amgen(2 entities) | 27 | $602 |
| Novo Nordisk | 27 | $491 |
| Exact Sciences | 14 | $333 |
| Amneal Pharmaceuticals LLC | 17 | $276 |
| Boehringer Ingelheim | 14 | $257 |
| Sanofi-aventis U.S. LLC | 8 | $200 |
| Xeris Pharmaceuticals, Inc. | 9 | $186 |
| Mannkind Corporation | 7 | $175 |
| Novartis | 6 | $146 |
| Abbott | 6 | $127 |
| Insulet Corporation | 5 | $108 |
| Radius Health, Inc. | 4 | $107 |
| Johnson & Johnson | 5 | $82 |
| Merck | 5 | $72 |
| Dexcom, Inc. | 4 | $72 |
| Medtronic | 2 | $44 |
| Pfizer | 3 | $38 |
| Phadia US Inc. | 1 | $35 |
| Sequel Med Tech, LLC | 1 | $28 |
| Boston Scientific | 1 | $28 |
| Neurocrine Biosciences, Inc. | 1 | $27 |
| Recordati_rare_diseases_inc. | 1 | $26 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| Bayer | 1 | $24 |
| Shire North American Group Inc | 1 | $22 |
| IBSA Pharma Inc. | 1 | $21 |
| Corcept Therapeutics | 1 | $20 |
| Kowa Pharmaceuticals America, Inc. | 1 | $19 |
| Amarin Pharma, Inc. | 1 | $18 |
| Companion Medical, Inc. | 1 | $17 |
| Tandem Diabetes Care, Inc. | 1 | $16 |
| Astellas Pharma US Inc | 1 | $15 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $15 |
| Madrigal Pharmaceuticals | 1 | $14 |
| Vivus LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEPEZZA$107
How this compares
$5,330 in reported general payments places this provider in the 55th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
See all endocrinology, diabetes & metabolism providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 310 | $406,645 |
| OzempicSemaglutide | 121 | $188,955 |
| JardianceEmpagliflozin | 109 | $149,607 |
| JanuviaSitagliptin Phosphate | 47 | $73,559 |
| Tresiba Flextouch U-200Insulin Degludec | 86 | $64,922 |
| TradjentaLinagliptin | 53 | $60,033 |
| Tresiba Flextouch U-100Insulin Degludec | 84 | $55,892 |
| TrulicityDulaglutide | 35 | $52,072 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 21 | $30,735 |
| RybelsusSemaglutide | 11 | $24,456 |
| Humalog Kwikpen U-100Insulin Lispro | 51 | $17,958 |
| Repatha SureclickEvolocumab | 12 | $17,465 |
| SynthroidLevothyroxine Sodium | 135 | $14,956 |
| FarxigaDapagliflozin Propanediol | 11 | $14,204 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 95 | $14,120 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $845 | $466,074371 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $491 | $221,312148 claims |
| Boehringer IngelheimJardiance, Tradjenta | $257 | $209,640162 claims |
| MerckJanuvia | $72 | $73,55947 claims |
| AstraZenecaFarxiga | $788 | $14,20411 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $276 | $4,704476 claims |
| Sanofi-aventis U.S. LLCLantus | $200 | $3,19812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
Other endocrinology, diabetes & metabolism in Boca Raton
- Irina RobinsonBoca Raton$65K
- Vineeth MohanBoca Raton$51K
- Jay SkylerMiami$2.2M
- Arelis MaderaPort Charlotte$1.7M
- Damon TantonOrlando$1.2M
- Gaston PonteMelbourne$906K
- Brian LakeLargo$888K
- David SuttonJacksonville$783K
- Mae Sheikh AliJacksonville$751K
- Richard PratleyOrlando$735K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.